| Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study (NCT07602907) | Zhejiang Cancer Hospital | 2026-08-04 |
| Research on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy (NCT07689929) | Zhejiang Cancer Hospital | 2026-08-01 |
| Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (NCT07691515) | Zhejiang Cancer Hospital | 2026-07-01 |
| Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer (NCT07702838) | Zhejiang Cancer Hospital | 2026-07-01 |
| A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer (NCT07586449) | Zhejiang Cancer Hospital | 2026-06-10 |
| Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies (NCT07670949) | Zhejiang Cancer Hospital | 2026-06-01 |
| Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer (NCT07673211) | Zhejiang Cancer Hospital | 2026-06-01 |
| Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases (NCT07343479) | Zhejiang Cancer Hospital | 2026-05-01 |
| CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. (NCT07538635) | Zhejiang Cancer Hospital | 2026-04-20 |
| Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma (NCT07554898) | Zhejiang Cancer Hospital | 2026-04-16 |
| Safety and Efficacy of Umbilical Cord Blood Therapy for Cancer Therapy-Induced Thrombocytopenia (CTIT) (NCT07441720) | Zhejiang Cancer Hospital | 2026-02-28 |
| Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma (NCT07416890) | Zhejiang Cancer Hospital | 2026-02-10 |
| A Phase II Clinical Study Evaluating the Effectiveness of Injectable NC527-X in Intraoperative Imaging for Patients With Solid Tumors (NCT07538648) | Zhejiang Cancer Hospital | 2025-12-24 |
| Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer (NCT07326150) | Zhejiang Cancer Hospital | 2025-12-08 |
| A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy (NCT07330544) | Zhejiang Cancer Hospital | 2025-11-24 |
| Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer (NCT07235930) | Zhejiang Cancer Hospital | 2025-11-15 |
| Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer (NCT07325630) | Zhejiang Cancer Hospital | 2025-11-03 |
| SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer (NCT07162714) | Zhejiang Cancer Hospital | 2025-10-27 |
| Development of a Pan-Cancer Screening Model Based on Blood Biomarkers (NCT07554157) | Zhejiang Cancer Hospital | 2025-10-22 |
| An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II) (NCT07196696) | Zhejiang Cancer Hospital | 2025-10-12 |
| A Real-world Study on the Compliance of OFS-assisted Endocrine Therapy for Hormone Receptor-positive(HR+) Premenopausal Breast Cancer (NCT07180914) | Zhejiang Cancer Hospital | 2025-10-10 |
| Study on Safety and Efficacy of UCB-MNCs for Chronic Radiation Enteritis (NCT07175207) | Zhejiang Cancer Hospital | 2025-10-01 |
| Study on Safety and Efficacy of UCB-MNCs for Radiation-induced Lung Injury (NCT07177456) | Zhejiang Cancer Hospital | 2025-10-01 |
| Real-Time Dynamic Imaging Study of Normal Pharyngolaryngeal Structures During Barium Swallow (GLAM-III) (NCT07264322) | Zhejiang Cancer Hospital | 2025-09-10 |
| Effect of Small Double-lumen Tube on the Intubation Time of Thoracoscopic Pulmonectomy in Asian Women (NCT07097584) | Zhejiang Cancer Hospital | 2025-07-28 |
| Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer (NCT07074353) | Zhejiang Cancer Hospital | 2025-07-20 |
| a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer . (NCT07035808) | Zhejiang Cancer Hospital | 2025-07-01 |
| Clinical Evaluation of GRAPE Model for Gastric Cancer Screening (NCT07067983) | Zhejiang Cancer Hospital | 2025-05-30 |
| Effect of Trendelenburg Positioning on Anesthesia-Induced Hypotension in Elderly Patients (NCT06968091) | Zhejiang Cancer Hospital | 2025-05-16 |
| Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma (NCT06918015) | Zhejiang Cancer Hospital | 2025-05-01 |
| IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer (NCT07692750) | Zhejiang Cancer Hospital | 2025-04-30 |
| SH-LPS System in Preoperative Planning for Liver Resection (NCT06911086) | Zhejiang Cancer Hospital | 2025-04-15 |
| Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases (NCT06861218) | Zhejiang Cancer Hospital | 2025-04-01 |
| Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma (NCT06741020) | Zhejiang Cancer Hospital | 2025-03-01 |
| A Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer (NCT07455188) | Zhejiang Cancer Hospital | 2025-03-01 |
| Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL (NCT06832267) | Zhejiang Cancer Hospital | 2025-02-14 |
| To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China. (NCT06784921) | Zhejiang Cancer Hospital | 2025-02-01 |
| Phase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy (NCT07284836) | Zhejiang Cancer Hospital | 2025-02-01 |
| Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment (NCT07285941) | Zhejiang Cancer Hospital | 2025-01-04 |
| Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC (NCT06752382) | Zhejiang Cancer Hospital | 2024-12-31 |
| Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery (NCT06704698) | Zhejiang Cancer Hospital | 2024-12-03 |
| Pharmacokinetic Study of Tranexamic Acid (NCT06728670) | Zhejiang Cancer Hospital | 2024-11-20 |
| RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL (NCT06674096) | Zhejiang Cancer Hospital | 2024-11-06 |
| A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC (NCT06478043) | Zhejiang Cancer Hospital | 2024-10-16 |
| Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer (NCT06624878) | Zhejiang Cancer Hospital | 2024-10-08 |
| GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC (NCT06611826) | Zhejiang Cancer Hospital | 2024-09-30 |
| Different Intraoperative Blood Pressure Management on Postoperative Cognitive Function in Tumor Patients（PRECISION） (NCT06711432) | Zhejiang Cancer Hospital | 2024-09-18 |
| Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens (NCT06572319) | Zhejiang Cancer Hospital | 2024-09-01 |
| Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL (NCT06832228) | Zhejiang Cancer Hospital | 2024-09-01 |
| Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer (NCT07271823) | Zhejiang Cancer Hospital | 2024-09-01 |
| Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study (NCT06538896) | Zhejiang Cancer Hospital | 2024-08-20 |
| Effect of Esketamine on Anxiety State in Patients Undergoing Abdominal Tumor Surgery (NCT06530706) | Zhejiang Cancer Hospital | 2024-08-05 |
| Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial） (NCT06509568) | Zhejiang Cancer Hospital | 2024-08-01 |
| Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer (NCT06562920) | Zhejiang Cancer Hospital | 2024-07-24 |
| Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients (NCT06650332) | Zhejiang Cancer Hospital | 2024-07-10 |
| ctDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: A Single-center, Randomized, Controlled Study (NCT06609551) | Zhejiang Cancer Hospital | 2024-07-03 |
| Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (NCT06413342) | Zhejiang Cancer Hospital | 2024-06-01 |
| Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy (NCT06419140) | Zhejiang Cancer Hospital | 2024-06-01 |
| Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer (NCT06437678) | Zhejiang Cancer Hospital | 2024-05-27 |
| Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (NCT06422858) | Zhejiang Cancer Hospital | 2024-05-20 |
| GMA-Tulip, I-gel and the LMA-Supreme (LMA-S) Devices in Airway Management (GLAM-I) (NCT06383494) | Zhejiang Cancer Hospital | 2024-04-30 |
| Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma (NCT06364826) | Zhejiang Cancer Hospital | 2024-04-22 |
| Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer (NCT06254066) | Zhejiang Cancer Hospital | 2024-04-16 |
| Ciprofol EC50 for Inducing Loss of Consciousness in Elderly Patients (NCT06253078) | Zhejiang Cancer Hospital | 2024-04-02 |
| A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer (NCT06292689) | Zhejiang Cancer Hospital | 2024-03-22 |
| A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies. (NCT06349044) | Zhejiang Cancer Hospital | 2024-03-20 |
| Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial (NCT06308939) | Zhejiang Cancer Hospital | 2024-03-08 |
| Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer (NCT06300489) | Zhejiang Cancer Hospital | 2024-03-03 |
| Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy (NCT06272214) | Zhejiang Cancer Hospital | 2024-03-01 |
| SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma (NCT06199882) | Zhejiang Cancer Hospital | 2024-02-01 |
| The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity (NCT06214195) | Zhejiang Cancer Hospital | 2024-01-20 |
| Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC (NCT06195670) | Zhejiang Cancer Hospital | 2024-01-01 |
| Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone (NCT06173466) | Zhejiang Cancer Hospital | 2023-12-15 |
| Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study. (NCT06195683) | Zhejiang Cancer Hospital | 2023-12-01 |
| The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial. (NCT06140576) | Zhejiang Cancer Hospital | 2023-11-30 |
| LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals (NCT07252362) | Zhejiang Cancer Hospital | 2023-11-11 |
| Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma (NCT06092645) | Zhejiang Cancer Hospital | 2023-10-30 |
| A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC (NCT06190639) | Zhejiang Cancer Hospital | 2023-10-25 |
| Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC (NCT06350162) | Zhejiang Cancer Hospital | 2023-10-18 |
| A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL (NCT06086197) | Zhejiang Cancer Hospital | 2023-10-01 |
| Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma (NCT06055816) | Zhejiang Cancer Hospital | 2023-09-28 |
| Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy (NCT06031597) | Zhejiang Cancer Hospital | 2023-09-15 |
| 3D Printed Models for Liver Surgery (NCT06006338) | Zhejiang Cancer Hospital | 2023-09-15 |
| Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy (NCT06048289) | Zhejiang Cancer Hospital | 2023-09-14 |
| A Multi-omics-based Metabolic Typing Study of Gastric Cancer (NCT06134011) | Zhejiang Cancer Hospital | 2023-09-10 |
| Fruquintinib Combined With Chemotherapy as Third-line /Third-line+ Treatment in Advanced Colorectal Cancer (NCT05928312) | Zhejiang Cancer Hospital | 2023-08-28 |
| Advanced Pancreatic Cancer (NCT05958849) | Zhejiang Cancer Hospital | 2023-08-01 |
| Cetuximab in Combination With Dabrafenib and Tislelizumab in BRAF Mutated Treatment of Advanced Colorectal Cancer (NCT05963087) | Zhejiang Cancer Hospital | 2023-08-01 |
| Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation (NCT06178926) | Zhejiang Cancer Hospital | 2023-08-01 |
| Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial. (NCT06133088) | Zhejiang Cancer Hospital | 2023-08-01 |
| Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors (NCT05920863) | Zhejiang Cancer Hospital | 2023-07-01 |
| Combined Treatment of Treated Bile Duct Cancer (NCT05911425) | Zhejiang Cancer Hospital | 2023-07-01 |
| Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma (NCT05903456) | Zhejiang Cancer Hospital | 2023-07-01 |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC (NCT05896059) | Zhejiang Cancer Hospital | 2023-05-15 |
| GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence (NCT05557578) | Zhejiang Cancer Hospital | 2023-05-05 |
| Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer (NCT06393166) | Zhejiang Cancer Hospital | 2023-05-01 |
| Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma (NCT06383533) | Zhejiang Cancer Hospital | 2023-05-01 |
| Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma (NCT05813626) | Zhejiang Cancer Hospital | 2023-04-21 |
| Multi-omics Study of Tongue Coating in Malignant Tumors of Digestive Tract (NCT05794841) | Zhejiang Cancer Hospital | 2023-04-01 |
| The Formulation of Compound Phellinus Igniarius Decoction on Radiation Pneumonitis (NCT06861179) | Zhejiang Cancer Hospital | 2023-03-22 |